Scholarlink

Objectives <p>Incomplete MRI sequences pose a significant challenge to the reliability of multiparametric MRI (mp-MRI) radiomics models. This study aimed to develop a robust and noninvasive approach for accurate glioma grading and isocitrate dehydrogenase (IDH) mutation status prediction using incomplete MRI data.</p> Materials and methods <p>Conventional MRI scans of 2170 glioma patients were retrospectively collected from five clinical institutions and a public dataset. Radiomic features extracted from each sequence, including incomplete ones, were processed using a robust incomplete sequence estimation network (RISEN). This model imputes missing features and learns latent fusion representations for glioma grading and IDH mutation status prediction. Model performance was evaluated by determining the optimal combination of mp-MRI sequences and simulating various clinical scenarios with different rates of missing data, using the area under the curve (AUC).</p> Results <p>The optimal sequence combination of T1WI, CE-T1WI, and T2-FLAIR achieved the highest performance for glioma grading (AUC: 0.8160, 0.9136, 0.8031) and IDH prediction (AUC: 0.8657, 0.8731, 0.7682) in internal and external validation datasets with complete data. In simulated incomplete-sequence scenarios, RISEN exhibited only moderate declines for glioma grading (mean AUC: 0.7942, 0.8955, 0.7759) and IDH prediction (mean AUC: 0.8454, 0.8478, 0.7414). Comparable robustness was observed in real-world missing-sequence data (AUC: 0.8910 and 0.8854, respectively).</p> Conclusion <p>RISEN demonstrates robust and clinically applicable performance for glioma grading and IDH mutation prediction across multiple cohorts, even under commonly encountered incomplete mp-MRI conditions.</p> Key Points <p><Emphasis Type="BoldItalic">Question</Emphasis> <i>Incomplete MRI sequences present a major challenge for radiomics-based glioma grading and IDH mutation status prediction in real-world clinical settings.</i></p> <p><Emphasis Type="BoldItalic">Findings</Emphasis> <i>The proposed RISEN model imputes missing features using latent representations, improving model robustness and maintaining high predictive performance across various missing data scenarios.</i></p> <p><Emphasis Type="BoldItalic">Clinical relevance</Emphasis> <i>RISEN offers a reliable solution for real-world glioma diagnosis when MRI sequences are incomplete, ensuring consistent clinical decision-making and personalized therapy planning across diverse imaging conditions.</i></p> Graphical Abstract <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Robust deep learning for incomplete MRI sequences in glioma grading and IDH mutation status prediction: a large-scale multicenter study

  • 期刊论文

  • 发表日期：

    2026年5月16日

查看全文
  • Fangrong Liang,
  • Jing Yan,
  • Shengsheng Lai,
  • Chaoli Zhang,
  • Jiaxin Lin,
  • Ruili Wei,
  • Yuankui Wu,
  • Jingliang Cheng,
  • Yaou Liu,
  • Wensheng Wang,
  • Xin Zhen,
  • Ruimeng Yang

摘要

Objectives

Incomplete MRI sequences pose a significant challenge to the reliability of multiparametric MRI (mp-MRI) radiomics models. This study aimed to develop a robust and noninvasive approach for accurate glioma grading and isocitrate dehydrogenase (IDH) mutation status prediction using incomplete MRI data.

Materials and methods

Conventional MRI scans of 2170 glioma patients were retrospectively collected from five clinical institutions and a public dataset. Radiomic features extracted from each sequence, including incomplete ones, were processed using a robust incomplete sequence estimation network (RISEN). This model imputes missing features and learns latent fusion representations for glioma grading and IDH mutation status prediction. Model performance was evaluated by determining the optimal combination of mp-MRI sequences and simulating various clinical scenarios with different rates of missing data, using the area under the curve (AUC).

Results

The optimal sequence combination of T1WI, CE-T1WI, and T2-FLAIR achieved the highest performance for glioma grading (AUC: 0.8160, 0.9136, 0.8031) and IDH prediction (AUC: 0.8657, 0.8731, 0.7682) in internal and external validation datasets with complete data. In simulated incomplete-sequence scenarios, RISEN exhibited only moderate declines for glioma grading (mean AUC: 0.7942, 0.8955, 0.7759) and IDH prediction (mean AUC: 0.8454, 0.8478, 0.7414). Comparable robustness was observed in real-world missing-sequence data (AUC: 0.8910 and 0.8854, respectively).

Conclusion

RISEN demonstrates robust and clinically applicable performance for glioma grading and IDH mutation prediction across multiple cohorts, even under commonly encountered incomplete mp-MRI conditions.

Key Points

Question Incomplete MRI sequences present a major challenge for radiomics-based glioma grading and IDH mutation status prediction in real-world clinical settings.

Findings The proposed RISEN model imputes missing features using latent representations, improving model robustness and maintaining high predictive performance across various missing data scenarios.

Clinical relevance RISEN offers a reliable solution for real-world glioma diagnosis when MRI sequences are incomplete, ensuring consistent clinical decision-making and personalized therapy planning across diverse imaging conditions.

Graphical Abstract